AAPS/RAPS/CAPRA collaborative program: exploring the challenges of drug regulation in a global environment: clinical concerns.
Globalization of the pharmaceutical industry has led to a need to harmonize the regulatory requirements governing the marketing of medicinal products. To minimize the barriers impeding global drug product registration, the International Conference on the Harmonization of Technical Requirements of Pharmaceuticals for Human Use (ICH) was established in 1990. The ICH has developed a series of guidelines that reflect agreements reached by participating nations on aspects of the chemistry and clinical technical sections that will fulfill the regulatory requirements of these various jurisdications. Nevertheless, there continue to be points of divergent perspectives and barriers that can impede the use of foreign clinical data. Given the importance of these issues, the Regulatory Science (RS) section of the American Association of Pharmaceutical Scientists (AAPS), in conjunction with the Regulatory Affairs Professional Society (RAPS) and the Canadian Association of Professional Regulatory Affairs (CAPRA) cosponsored a public forum on this topic. This manuscript provides a summary of the speaker presentations and audience discussions regarding the design of clinical trials and the extrapolation of results from these trials to support international drug registration.
Martinez
Marilyn N
MN
Center for Veterinary Medicine, Food and Drug Administration, Rockville, MD 20855, USA. mmartin1@cvm.fda.gov
McGilveray
Iain
I
D002986:Clinical Trials as Topic / Q000379:methods; D017277:Drug Approval; D004345:Drug Industry; D011307:Drug Prescriptions; D004335:Drug and Narcotic Control / Q000379:methods* / Q000458:organization & administration; D004777:Environment; D005006:Ethnicity; D006801:Humans; D007391:International Cooperation; D014774:Virulence